Moleculin Announces Approval for Third Drug to Commence Clinical Trials
February 07 2019 - 7:30AM
MBRX will now have three distinctive
oncology drugs in clinic in four ongoing clinical
trials
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the
"Company"), a clinical stage pharmaceutical company focused on the
development of oncology drug candidates, all of which are based on
license agreements with The University of Texas System on behalf of
the M.D. Anderson Cancer Center, today announced it has received
approval to begin clinical trials in Poland for its STAT3
inhibitor, WP1220, for the topical treatment of Cutaneous T-Cell
Lymphoma (“CTCL”).
“This marks an important milestone for
Moleculin. We now have three unique drug candidates in four ongoing
clinical trials for the potential treatment of rare and difficult
cancers,” commented Walter Klemp, Moleculin’s Chairman and CEO. “We
are committed to the strategy of what we call ‘multiple shots on
goal,’ and this latest approval to begin trials means we now have
three distinctly different therapies in clinical trials for the
potential treatment of rare and difficult cancers.”
Dr. Don Picker, Moleculin’s Chief Science
Officer, added, “CTCL is a potentially deadly form of skin cancer
involving skin lesions that often have high levels of activated
STAT3 (p-STAT3). As a potent inhibitor of p-STAT3, we believe
WP1220 may be ideally suited to treat these lesions through topical
application, which is what this clinical trial is designed to
evaluate.”
Dr. Malgorzata Sokolowska-Wojdylo, Dermatology
Department Chair at the Medical University of Gdańsk in Poland, and
the Principal Investigator running this clinical trial, concluded,
“There is a significant unmet need for improved topical therapies
for CTCL, and we are excited to be the first clinic to evaluate
this promising new drug in CTCL patients.”
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage
pharmaceutical company focused on the development of oncology drug
candidates, all of which are based on discoveries made at M.D.
Anderson Cancer Center. The Company’s clinical stage drugs are
Annamycin, an anthracycline designed to avoid multidrug resistance
mechanisms with little to no cardiotoxicity being studied for the
treatment of relapsed or refractory acute myeloid leukemia, more
commonly referred to as AML, and WP1066, an immuno-stimulating
STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML.
Moleculin Biotech is also engaged in preclinical development of
additional drug candidates, including additional STAT3 inhibitors
and compounds targeting the metabolism of tumors.
For more information about the Company, please visit
http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, the ability of
Moleculin to successfully recruit sufficient patients to complete
this clinical trial and that ability of WP1220 to show safety and
efficacy in patients. Although Moleculin Biotech believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Moleculin Biotech has attempted to
identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements are
only predictions and involve known and unknown risks,
uncertainties, and other factors, including those discussed under
Item 1A. "Risk Factors" in our most recently filed Form 10-K filed
with the Securities and Exchange Commission (“SEC”) and updated
from time to time in our Form 10-Q filings and in our other public
filings with the SEC. Any forward-looking statements contained in
this release speak only as of its date. We undertake no obligation
to update any forward-looking statements contained in this release
to reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
ContactsJoe Dorame, Robert Blum or Joe
DiazLytham Partners, LLC602-889-9700mbrx@lythampartners.com
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Sep 2023 to Sep 2024